MetaCap

NeoGenomics Inc. (NEO)

NASDAQ: NEOHealth CarePrecision InstrumentsUSD

14.82-0.27 (-1.79%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NEO stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.24
52-week range
7.07 – 20.15
Day range
14.63 – 15.14
Volume / Avg
1.18M / 1.96M
Beta
—

52-week range

$7.07$20.15

NEO stock today

On Nov 20, NEO ended the session at $14.82, shedding $0.27 (1.79%), versus the S&P 500's 3.70% decline. At this level, NEO sits in the middle of its 52-week range of $7.07 to $20.15: 26.5% below the high, set on Oct 6, 2026 and 109.6% above the low. NEO is up 26.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 29.1%.

NeoGenomics has posted a net loss over the last twelve months (EPS of -$0.24), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About NeoGenomics

Company profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

Industry
Precision Instruments
CEO
Mr. Anthony P. Zook
Headquarters
Fort Myers, FL
Employees
2,500

Financial highlights

Full financials

In fiscal 2025, NeoGenomics generated $727.3 million in revenue, up 10.1% from fiscal 2024, its 10th consecutive year of revenue growth. NeoGenomics reported a net loss of $108.0 million, compared with a loss of $78.7 million a year earlier. Gross margin was 43.2% (down from 43.9%) and operating margin -15.9%.

NeoGenomics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$727.33M$660.57M$591.64M$509.73M$484.33M
Growth+10.11%+11.65%+16.07%+5.24%+8.97%
Net income$-108.03M$-78.73M$-87.97M$-144.25M$-8.35M
EPS (diluted)$-0.84$-0.62$-0.70$-1.16$-0.07

Analyst forecast

Forecast

Consensus (11 analysts)

none

Avg. price target

$23.40+57.89%

  • Strong buy 2
  • Buy 6
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $19.00High $35.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 28, 2026
EPS actual vs est.
$-0.05 vs $-0.01
Surprise
-400.00%

NEO news

All NEO news

NeoGenomics peers

Health Care sector
NEO peer companies
CompanyPrice% ChgMarket capCompare
AIDX20/20 Biolabs Inc.0.1571-13.49%$2.20Mvs NEO
ULSUL Solutions Inc. Class A72.64-2.99%$14.67Bvs NEO

Indexes, lists and sector

NeoGenomics stock FAQ

What is NeoGenomics's stock price today?

NEO last traded at $14.82 as of Nov 20, 4:00 PM EST, down 1.79% on the day. Prices are delayed at least 15 minutes.

Who is NeoGenomics's CEO?

Mr. Anthony P. Zook is the chief executive officer of NeoGenomics Inc., which has about 2,500 employees.

What is the NEO 52-week high?

The 52-week high for NEO is $20.15 and the 52-week low is $7.07. The stock is currently 26.5% below its high.

Compare NEO